Umbilical cord
HUVEC/TERT66
Evercyte’s human umbilical vein endothelial cell line HUVEC/TERT66 is grown continuously under xeno-free conditions while maintaining expression of cell type specific markers and functions. Therefore, these cells can be used to study vascularization in response to hypoxic conditions in tumors or ischemic tissues, to assess interaction of endothelial cells with leukocytes, macrophages or mesenchymal stem cells and to perform toxicity studies as well as to test novel compounds for pro- or anti-angiogenic activities.
General information
Cat#: CHT-006-0066
Morphology and marker expression
HUVEC/TERT66 cells are characterized by the typical endothelial morphology and homogenous expression of cell-type specific markers such as vWF and CD31. Cell nuclei are counterstained with DAPI.
Differentiation on Matrigel and karyotype
When inoculated onto matrigel-matrix HUVEC/TERT66 cells form typical capillary like structures (left picture) demonstrating neoangiogenic potential. The cells show a normal, diploid karyotype (46, XY) as shown by COBRA FISH (right picture, kindly provided by Sheena Ong, Leiden University Medical Center).
FAQs
In vitro propagation
Endopan 300 SL Kit (PAN Biotech) supplemented with Panexin SL-S and G418
Endopan 300 SL (PAN Biotech, Cat# P04-0065K w/o GA)
Serum substitute Panexin SL-S (PAN Biotech, Cat# P04
Additional material & reagents
0,1 % Gelatin (Sigma, Cat# G1393, 2 %), diluted in PBS
Phosphate buffered saline (PBS) (Sigma, Cat# D8537)
Trypsin inhibitor (Gibco, Cat# R007100)
0,05 % Trypsin-EDTA (Gibco, Cat#25300-054)
Passaging of cells
The new culture flasks have to be pre-coated with gelatin. Therefore, the culture flasks are treated with 0.1 % gelatin solution (80 µl/cm²) at 37°C for at least 10 min (10 – 60 min). Before introducing cells, remove excess of gelatin solution.
Cryopreservation
Freezing medium
CryoStor® cell cryopreservation medium CS10 (Sigma Aldrich, Cat# C2874)
Additional material & reagents
Phosphate buffered saline (PBS) (Sigma, Cat# D8537)
0,05 % Trypsin-EDTA (Gibco, Cat# 25300-054)
Trypsin inhibitor (Gibco, Cat# R007100)
Freezing of cells
Detach the cells (about 90 % confluence) from the culture vessel by using Trypsin-EDTA and Trypsin-Inhibitor (Protocol passaging of HUVEC/TERT66).
Thawing of cells
Original Evercyte cells are to be thawed in a T25 roux flask
Product data sheet – certificate of analysis
Protocols
Data on Markers and Functions
Selected publications
Licence Conditions
The business concept of Evercyte is to out-license telomerized cells to our customers. The license conditions depend on whether the contract partner is a for profit or a nonprofit organization and the intended use of the cells.
Nonprofit organizations
On time payment for unlimited use: EUR 1600
Profit organizations
Pharmaceutical – chemical- cosmetic industries
Contract research organizations (CRO)
Initial license fee for 3 months: EUR 2500Annual license fee R&D: royalty based
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.